bluebird bio, Inc.

Thank you for standing by. My name is Pam, and I will be your conference operator today. At this time, I would like to welcome everyone to the Bluebird Bio second quarter 2024 results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star 1 again. Thank you. I would now like to turn the conference over to Courtney O'Leary of Investor Relations. You may begin.

Good morning, everyone, and thank you for joining our second quarter 2024 results call today. My name is Courtney O'Leary, Director of Investor Relations at Bluebird Bio. Before we begin, let me review our safe harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995, including expectations regarding our future financial results and financial position, in addition to statements of the company's plans, expectations, or intentions regarding regulatory progress, commercialization plans, and business operations. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors, that could cause actual results to differ materially from projected results. A description of these risks is contained in our filings at the SEC, which are available on the investor relations section of our website, www.bluebirdbio.com. On today's call, Andrew Obenshain, Bluebird Bio's CEO, will provide opening remarks. Then Tom Plima, Chief Commercial and Operating Officer, will provide updates on the commercial launches of Lufgenia, Zantaglo, and SkySona. And lastly, Bluebird CFO, James Sterling, will provide a financial update before opening the call-up for Q&A. With that, I will turn it over to Andrew.

Thanks, Courtney, and thank you, everyone, for joining our call this morning. Over the past year, Bluebird has built what we believe to be an unrivaled commercial gene therapy foundation with three ongoing launches. We've seen that translate into a robust network of qualified treatment centers, proven access and reimbursement, and demonstrated demand for our therapies for both patients and providers. Today, we'll provide you with additional insight into our commercial performance, grounded by a real-world experience that helps inform expectations and modeling for our launches. This morning, we announced that we've renegotiated our agreement with Hercules Capital, and on today's call, we will also provide you with details on our business execution and cash runway. I'll now hand it over to Tom to discuss the progress in our commercial launches in greater detail.